[1]MacDonald BT, Tamai K, He X.Wnt/beta-catenin signaling:components, mechanisms, and diseases[J].Dev Cell, 2009, 17 (1) :9-26.
|
[2]简易成, 熊伍军.Wnt诱导分泌蛋白-1与器官纤维化[J].国际消化病杂志, 2010, 30 (5) :297-299.
|
[3]Knigshoff M, Wilhelm J, Jahn A, et al.Wnt-inducible protein (WISP-1) is a key regulator of alveolar epithelial cell hyperplasia in pulmonary fibrosis[J].Eur Respir Rev, 2006, 15 (101) :180-181.
|
[4]Selman M, Pardo A, Barrera L, et al.Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis[J].Am J Respir Crit Care Med, 2006, 173 (2) :188-198.
|
[5]Knigshoff M, Kramer M, Balsara N, et al.WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis[J].J Clin Invest, 2009, 119 (4) :772-787.
|
[6]Colston JT, de la Rosa SD, Koehler M, et al.Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor[J].Am J Physiol Heart Circ Physiol, 2007, 293 (3) :H1839-1846.
|
[7]Venkatachalam K, Venkatesan B, Valente AJ, et al.WISP1, a pro-mitogenic, pro-survival factor, mediates tumor necrosis factor-alpha (TNF-alpha) -stimulated cardiac fibroblast proliferation but inhibits TNF-alpha-induced cardiomyocyte death[J].J Biol Chem, 2009, 284 (21) :14414-14427.
|
[8]Pennica D, Swanson TA, Welsh JW, et al.WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors[J].PNAS, 1998, 95 (25) :14717-14722.
|
[9]Berschneider B, Knigshoff M.WNT1 inducible signaling pathway protein 1 (WISP1) :A novel mediator linking development and disease[J].Int J Biochem Cell Biol, 2011, 43 (3) :306-309.
|
[10]Jiang F, Parsons CJ, Stefanovic B.Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation[J].J Hepatol, 2006, 45 (3) :401-409.
|
[11]熊伍军, 何益, 刘菲, 等.Wnt信号通路相关分子在肝纤维化中的表达水平变化及其意义[J].中华消化杂志, 2008, 28 (9) :612-616.
|
[1] | Zheng YongJian, Wang Yan. Histological assessment of reversal of liver fibrosis and cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(4): 709-713. doi: 10.3969/j.issn.1001-5256.2019.04.002 |
[2] | Qin Wei, Zhao CaiYan, Yang Zhao, Zhu SuPing, Li MuSong, Huo YuLing. Research advances in the role of OX40/OX40L in the immune pathogenesis of chronic hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(5): 1103-1106. doi: 10.3969/j.issn.1001-5256.2018.05.038 |
[3] | Chen YangYi, Liu ChengHai. Development and prospects of pathological classification systems for chronic hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(5): 1098-1102. doi: 10.3969/j.issn.1001-5256.2018.05.037 |
[4] | Tian AiPing, Yang YongFeng. A comparative analysis of pathological grading and staging systems for chronic hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2271-2277. doi: 10.3969/j.issn.1001-5256.2018.11.002 |
[5] | Sun Jing, Wang JingYun, Li QingQuan, Lu: MeiDe, Gao YanHang. Successful treatment of thrombocytopenia associated with chronic viral hepatitis: a report of two cases and literature review[J]. Journal of Clinical Hepatology, 2015, 31(2): 275-277. doi: 10.3969/j.issn.1001-5256.2015.02.032 |
[6] | Zhou XueLing, Yu ShuiPing. Role of Wnt signaling pathway in progression of liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(9): 1540-1542. doi: 10.3969/j.issn.1001-5256.2015.09.045 |
[7] | Expert Committee on Clinical Management of Adverse Reactions in Interferon-α Therapy for Chronic Viral Hepatitis . Expert consensus on clinical management of adverse reactions in interferon-α therapy for chronic viral hepatitis[J]. Journal of Clinical Hepatology, 2014, 30(11): 1106-1111. doi: 10.3969/j.issn.1001-5256.2014.11.003 |
[8] | Qin Hua, Wang WenZheng, Wang ZhanLan. Significance of ICGR15 and EHBF in evaluating liver reserve function among patients with chronic hepatitis[J]. Journal of Clinical Hepatology, 2014, 30(2): 141-144. doi: 10.3969/j.issn.1001-5256.2014.02.011 |
[9] | Ma LiXia, Wei XinHuan, Zhang Jing. Recent perspectives on the role of microRNAs of the miR-15 family in liver disease[J]. Journal of Clinical Hepatology, 2013, 29(2): 158-161. |
[10] | Yang HaiFeng, Xue Ling, Miao YiHui, Zheng CaiJuan, Yao ZuoYi, Zhang YanShu, Yao Lin. Expression and significance of caspase-8 in chronic hepatitis [J]. Journal of Clinical Hepatology, 2013, 29(2): 138-141. |
[11] | Yao XiXian, Yao DongMei. Combination treatment of Chinese traditional and Western medicine in chronic hepatitis and liver fibrosis[J]. Journal of Clinical Hepatology, 2013, 29(4): 245-248+252. |
[12] | Mu YongPing, Hu YiYang, Liu Ping. Making efforts to providing scientific evidence of therapeutic advantages of the combination of the Traditional Chinese and Western medicine in chronic hepatitis and cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(3): 161-163. |
[13] | Zhang XiuNa, Wang JunYu, Gao PuJun. Correlation of quantitative analysis of chronic hepatitis,nephritic syndrome,ascites and serum albumin[J]. Journal of Clinical Hepatology, 2012, 28(1): 33-34+47. |
[14] | Zhang JiMing, Mao WenShan. A case report of hepatic tuberculosis misdiagnosed as chronic hepatitis [J]. Journal of Clinical Hepatology, 2012, 28(11): 867-867. |
[15] | Gao BaoXiu, He Yong, Li GuiXing, Nie Xin, Luo TongXing, Song HaoLan. Analysis of relationship of chronic severe hepatitis with hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(7): 749-751. |
[16] | Shao Ying, Song GuangPing. Clinicopathological analysis of the development of hepatic sinusoidal capillarization in chronic hepatitis patients[J]. Journal of Clinical Hepatology, 2011, 27(2): 154-156. |
[17] | Cai WeiMin. Some problems in anti-fibrotic therapies[J]. Journal of Clinical Hepatology, 2011, 27(3): 225-232. |
[18] | Gu XiBing, Yang XiaoJuan, Zhu HongYing, Xu YueQin. Effect of medical ozone therapy in the hepatorenal syndrome in patients with chronic severe hepatitis[J]. Journal of Clinical Hepatology, 2010, 26(6): 598-601. |
[19] | Li Juan, Yu HongWei, Zhang Jian, Zhao Juan, Shi ShuYun, Meng QingHua. Clinical analysis of one case of slow increase subacute liver failure[J]. Journal of Clinical Hepatology, 2010, 26(6): 654-656. |